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Abstract
Recombinant human erythropoietins (rHuEPOs) are used to treat cancer-related anemia. Recent preclinical studies
and clinical trials, however, have raised concerns about the potential tumor-promoting effects of these drugs.
Because the clinical significance of erythropoietin receptor (EPOR) signaling in human non-small cell lung cancer
(NSCLC) also remains controversial, our aim was to study whether EPO treatment modifies tumor growth and if
EPOR expression has an impact on the clinical behavior of this malignancy. A total of 43 patients with stage III–IV
adenocarcinoma (ADC) and complete clinicopathological data were included. EPOR expression in human ADC
samples and cell lines was measured by quantitative real-time polymerase chain reaction. Effects of exogenous
rHuEPOα were studied on human lung ADC cell lines in vitro. In vivo growth of human ADC xenografts treated with
rHuEPOα with or without chemotherapy was also assessed. In vivo tumor and endothelial cell (EC) proliferation was
determined by 5-bromo-2’-deoxy-uridine (BrdU) incorporation and immunofluorescent labeling. Although EPOR
mRNA was expressed in all of the three investigated ADC cell lines, rHuEPOα treatment (either alone or in
combination with gemcitabine) did not alter ADC cell proliferation in vitro. However, rHuEPOα significantly decreased
tumor cell proliferation and growth of human H1975 lung ADC xenografts. At the same time, rHuEPOα treatment of
H1975 tumors resulted in accelerated tumor endothelial cell proliferation. Moreover, in patients with advanced stage
lung ADC, high intratumoral EPOR mRNA levels were associated with significantly increased overall survival. This
study reveals high EPOR level as a potential novel positive prognostic marker in human lung ADC.
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Introduction
Lung cancer, representing a major healthcare problem
worldwide [1], is currently classified into two major groups:
small cell and non-small cell lung cancer. The latter includes
large-cell carcinoma, squamous-cell carcinoma and ADC.
Approximately 85% of lung cancer patients have NSCLC and
ADC accounts for more than 40% of all lung cancer cases [2].
Although targeted drugs have been incorporated into NSCLC
therapeutic protocols, the overall prognosis of NSCLC patients
remains poor: the five-year survival rate has been at a plateau
of 15% for three decades. For this reason, a better
understanding of the biological mechanisms involved in lung
cancer development is urgently needed [3].
Cancer hypoxia has emerged as one of the key issues in
lung cancer progression, as it has profound effects on
angiogenesis, therapy resistance and cancer cell metabolism
[4]. At the same time, cancer-related anemia occurs frequently
in patients with lung cancer and leads to systemic and
intratumoral hypoxia [5]. It is now established that hypoxia
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enhances the aggressiveness of cancer cells and promotes
malignant progression. Moreover, tumor hypoxia has
fundamental effects not only on the prognosis but on
therapeutic responses as well [1]. Thus, attempts to correct the
intratumoral oxygen status of lung cancer patients are justified.
However, although rHuEPOs are effective drugs for correcting
anemia, recent clinical trials have suggested inferior overall
survival and/or locoregional control of tumors in patients
receiving rHuEPO [6]. In addition, human and experimental
studies have shown the co-expression of EPO/EPO receptor in
various human malignancies and also demonstrated that the
EPO/EPOR signaling plays a significant role in cancer cell
proliferation, migration, invasiveness, and in the inhibition of
apoptosis [7]. The EPOR expression in ECs has suggested
that EPO may stimulate angiogenesis as well.
As suggested in other recent studies, however, the overall
direct effect of EPO/EPOR signaling on tumor progression and
therapy is not straightforward. For instance, in a preclinical
myeloma model, rHuEPO induced tumor regression and
antitumor immune responses [8]. In another study, kidney
carcinoma and myelomonocytic leukemia cell lines treated with
rHuEPO exhibited an increase in apoptosis in response to
chemotherapy [9].
To make the picture more complex, although certain clinical
studies using commercially available anti-EPOR antibodies
have suggested a relationship between EPOR expression and
adverse clinical outcome following treatment with EPOs, most
studies of EPOR detection in tumor tissues have provided false
positive results because of the lack of EPOR specific
antibodies (reviewed in ref [10].). Saintigny et al., for example,
showed that EPO/EPOR co-expression is associated with poor
survival in stage I NSCLC and suggested a potential role of
endogenous EPO in the progression of these tumors [11]. Data
from several other groups suggest, however, that the antibody
used in the study of Saintigny et al. (C-20, SC-695; Santa Cruz,
CA) is not valid for determining the EPOR status of tissue
sections [12]. On the other hand, recent evidence also
suggests that EPOR downregulation in NSCLC is
compromised due to the lack of EPOR ubiquitination following
EPO stimulation [13] and that increased pre-operative plasma
EPO levels are associated with reduced survival in NSCLC
patients [14]. EPO expression and EPO/EPOR co-expression
were also found to be associated with poor loco-regional
control and survival in irradiated stage II/III NSCLC patients
[15]. Overall, because these findings warrant additional
research of EPOR signaling in NSCLC, our aim was to
examine the association between EPOR expression and the
course of disease in human lung ADC.
Results
EPOR expression and in vitro cell proliferation studies
EPOR mRNA levels of H1975, H1650 and H358 human
ADCs were determined by using quantitative real-time PCR
(qRT-PCR) analyses. HUVEC (human umbilical vein
endothelial cell) and K562 erythroleukemia cell lines served as
positive controls. H1650 and H358 lines expressed EPOR at
low level. However, H1975 cells expressed EPOR mRNA at
higher level than K562 cells (Figure 1A).
To investigate whether EPO influences ADC cell growth in
an autocrine manner, the effect of treatments with different
rHuEPOα doses was studied on three human ADC cell lines.
Importantly, rHuEPOα did not stimulate the in vitro proliferation
rate of any of the three cell lines when compared with
untreated cells after 48 hours (Figure 1 B-D).
As expected, treatment with gemcitabine (1, 10 µg/ml)
significantly decreased cell proliferation in all examined human
ADC lines (p < 0.001). rHuEPOα alone did not alter cell
proliferation and the anti-proliferative effect of gemcitabine was
not affected by rHuEPOα at any concentrations (Figure 1 B-D).
In vivo effect of rHuEPOα and gemcitabine treatments
Next, we sought to study the effect of rHuEPOα on the in
vivo growth of the H1975 cell line that showed the highest in
vitro EPOR expression. Therefore, in our next set of
experiments, the growth rates of subcutaneously implanted
H1975 tumors after rHuEPOα or gemcitabine treatments alone
or in combination were assessed. Tumor growth was
significantly decreased in mice treated with gemcitabine alone.
Surprisingly, a less robust but still significant growth-inhibitory
effect of rHuEPOα was observed when administered alone.
However, no additional synergistic effects could be achieved
when the two drugs were given in combination (Figure 2 A-B).
The mean tumor weights in the control, rHuEPO, gemcitabine
and gemcitabine plus rHuEPO treated groups were 0.938 g,
0.45 g, 0.039 g and 0.024 g, respectively (Figure 2 C).
In mice treated with rHuEPOα alone, the proliferation index
of H1975 cells and mouse blood vessel ECs was determined
by BrdU labeling (Figure 3 A-B). rHuEPOα not only resulted in
accelerated EC proliferation in vivo (Figure 3 C) but surprisingly
it also significantly decreased the in vivo growth rate of the high
EPOR receptor-expressing H1975 NSCLC cells (Figure 2 A-B).
Association of bronchoscopy brush EPOR mRNA
expressions with clinicopathological parameters
To determine the clinical relevance of tumor tissue EPOR
expression, we performed comparative statistical analysis of
bronchial brush EPOR mRNA expression and
clinicopathological variables. In line with the findings of Yasuda
et al. [16], our preliminary studies revealed a significant
variability in normal lung tissue EPOR expressions. Therefore,
we normalized tumor tissue EPOR expressions to the patient-
matched normal endobronchial EPOR expression levels (T/N)
(Figure S1). No significant associations with age, smoking
history, gender, stage or treatment were detected (Table 1).
EPOR expression level as a prognostic marker
Next we used Kaplan-Meier analysis to calculate the overall
survival rates for advanced stage ADC patients with low and
high EPOR levels. We elucidated that ADC patients with high
EPOR levels had significantly longer survival than those with
low EPOR expression (median survival was 11 versus 6
months, respectively; p = 0.035; Figure 4). Multivariate analysis
(including standard prognostic variables, such as age, gender,
tumor stage and smoking history) also indicated that
EPOR Expression in Lung Adenocarcinoma
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pretreatment EPOR levels predicted outcome independent of
other variables (p = 0.031; Table 2). A further independent
prognostic factor related to poor survival was patients' age and
gender (p = 0.012 and 0.018, respectively, Table 2).
Discussion
Although EPOR is widely expressed in malignant tumors
including human NSCLC, the significance of EPOR signaling in
this malignancy is not fully elucidated. Therefore, we assessed
EPOR mRNA expression levels in bronchoscopy brush
samples of stage III-IV ADC patients, and investigated whether
these levels might be related to patient’s clinicopathological
variables and/or prognosis. This study presents the novel
finding that advanced stage pulmonary ADC patients with high
EPOR mRNA expressions have significantly better prognosis
than those with low EPOR levels.
EPOR is expressed in non-hematopoietic tissues suggesting
that EPO has pleiotropic effects extending well beyond
erythropoiesis. EPOR is also expressed in various cancer cell
lines (including NSCLC) and in human tumor tissues including
stromal components such as the vasculature [7]. Iatrogenic
effects of rHuEPO via EPOR signaling resulting in potentially
accelerated tumor cell proliferation and angiogenesis may,
thus, compete with rHuEPO’s beneficial effects. In accordance
with results of previous studies [13,17–20], although EPOR
was also present at the mRNA level in all our investigated
human lung ADC cell lines, exogenous rHuEPOα (either alone
or in combination with gemcitabine) did not have an effect on
ADC cell growth in vitro. Unexpectedly, however, rHuEPOα
alone significantly decreased tumor cell proliferation and
growth of human xenograft tumors formed by H1975 cells (with
the highest EPOR expression among the investigated ADC cell
lines). The reasons for this in vivo antitumoral effect of
Figure 1.  EPOR is expressed in human lung ADC cell lines but exogenous rHuEPOα does not modify ADC cell
proliferation in vitro.  (A) Real-time qRT-PCR demonstrating the expression of EPOR mRNA in human lung ADC cell lines and
K562 and HUVEC cells as control. The highest EPOR expression level was detected in the H1975 ADC cell line. H1975 (B), H1650
(C) and H358 (D) cells were treated with rHuEPOα at different concentrations (1, 3 IU/ml) with or without gemcitabine (1, 10 µg/ml).
Cell numbers were estimated at 48 hours by sulforhodamine B colorimetric assay. Although gemcitabine significantly decreased the
proliferation of ADC cells (p < 0.001), rHuEPO treatment (either alone or in combination with gemcitabine) did not modify ADC cell
proliferation in vitro.
doi: 10.1371/journal.pone.0077459.g001
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rHuEPOα are not fully understood. One possible explanation
can be that rHuEPOα corrected intratumoral hypoxia which, in
turn, might have inhibited the activation of the major hypoxia
regulator, hypoxia-inducible factor (HIF)-1α [21]. The observed
parallel and significant increase of tumor EC proliferation (and
supposedly the consequent increase in intratumoral capillary
surface) in H1975 xenografts supports this scenario. In line
with this, our group has demonstrated previously that in human
colon (HT25) and epidermoid carcinoma (A431) xenograft
models, rHuEPOα administration significantly decreased
tumoral hypoxia and HIF-1α and vascular endothelial growth
factor (VEGF) expressions but had no effect on tumor growth.
Figure 2.  Exogenous rHuEPOα reduced in vivo growth of human lung adenocarcinoma cells in SCID mice.  (A) Growth
curves and (C) tumor weights of control, rHuEPOα (150 IU/kg), gemcitabine (100 mg/kg) and rHuEPOα (150 IU/kg) plus
gemcitabine (100 mg/kg) groups; *p < 0.05 versus control; **p < 0.001, versus control. (B) Surgically removed H1975 xenografts at
the end of the experiment (day 33).
doi: 10.1371/journal.pone.0077459.g002
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Figure 3.  Effect of rHuEPOα and gemcitabine treatments on the proliferation of endothelial and tumor cells in H1975
xenograft tumors.  Representative immunofluorescent images of tumors from control (A) and rHuEPOα-treated (B) mice. Tumor
sections are stained for the endothelial marker, CD31 (green), the proliferation-associated marker, BrdU (red) and for TOTO-3
(blue) highlighting EC as well as tumor cell nuclei. Arrows in (B) point at proliferating endothelial cells. (C) Labeling index of tumor
and endothelial cells in 33-day-old rHuEPOα-treated or control H1975 tumors. *p = 0.021, versus controls; **p < 0.001, versus
controls.
doi: 10.1371/journal.pone.0077459.g003
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At the same time, rHuEPOα significantly increased the
proliferation of tumor-associated ECs and the diameter of
intratumoral blood vessels. The increased vessel surface
resulted in improved drug delivery to tumor cells and
augmented the antitumoral effects of chemotherapy [22]. In a
more recent study, we also found that rHuEPOα did not modify
the in vitro proliferation of EPOR expressing A431 tumor cells
but enhanced the effect of irradiation on proliferation, apoptosis
and clonogenic capacity. In the same study, treatment with
rHuEPOα alone decreased tumoral HIF-1α expression but had
no effect on tumor growth. However, rHuEPOα significantly
increased the efficacy of radiotherapy in vivo [23].
Association between EPOR signaling and disease outcome,
including survival, has hitherto been studied in only a small
number of NSCLC patients [11,24]. In addition, the only two
studies on the prognostic value of EPOR expression in human
NSCLC samples [24] were based on tumor
immunohistochemistry data generated with anti-EPOR
antibodies the specificity of which has been questioned so far
[12]. By using the most frequently used antibodies (M-20,
Santa Cruz Biotechnologies; MAB307, R&D Systems; and A82,
kindly provided by Amgen), we also attempted to measure
EPOR expression at the protein level in our human lung ADC
Table 1. Correlation of clinicopathologic features and
EPOR expression in ADC (n=43).
 
No. of patients with
ADC (%) EPOR expression (T/N) P value
  Low (%)a High (%)a  
All patients 43 (100%) 28 (65.1%) 15 (34.9%)  
Age (years) b     
61< 20 (46.5) 13 (46.4) 7 (46.7)  
61≥ 23 (53.5) 15 (53.6) 8 (53.3) 0.99 c
Smoking*     
Non-smoker 2 (4.7) 1 (3.6) 1 (6.7)  
Current or ex-smoker 30 (69.8) 21 (75) 9 (60) 0.53 d
Gender     
Male 19 (44.2) 13 (46.4) 6 (40)  
Female 24 (55.8) 15 (53.6) 9 (60) 0.69 c
Stage     
III 14 (32.6) 9 (32.1) 5 (33.3)  
IV 29 (67.4) 17 (60.7) 10 (66.7) 0.93 c
Treatment**     
PBC 15 (34.9) 7 (25) 8 (53.3)  
RCT 12 (27.9) 10 (35.7) 2 (13.3)  
PT 9 (20.9) 6 (21.4) 3 (20)  
Surgery 3 (7) 2 (7.1) 1 (6.7)  
S+CT and/or RT 1 (2.3) 1 (3.6) 0 (0) 0.34 c
a T/N is the ratio of tumor tissue and normal tissue expression. Low expression is
defined below one; b Cut-off value is median value; c Chi-square test; d Fisher’s
exact test; Data shown in parentheses are column percentages; ADC,
adenocarcinoma; PBC, Platinum-Based chemotherapy; RCT, Radiochemotherapy;
PT, Palliative therapy; CT, chemotherapy; RT, radiotherapy; * 11 ADC patients had
unknown smoking status; ** there was no available information in case of 3 ADC
patients
doi: 10.1371/journal.pone.0077459.t001
cell lines. However, we either detected various nonspecific
signals (M-20 and MAB307) or failed to show any signs of
EPOR protein expression (A82) by Western blot analysis in our
ADC cell lines (data not shown). This observation is in
accordance with the data of Elliott et al. who found that the
currently available anti-EPOR antibodies have limited utility for
detecting EPOR [25]. It is also important to mention that the
posttranslational processing and alternative splicing also
modify the structure of EPOR [26,27]. This might be an
additional explanation for the lack of specific anti-EPOR
antibodies. Our analysis of EPOR expression in human ADC
samples based on qRT-PCR, thus, provides a more reliable
picture on the role of EPOR signaling in human ADC. More
precisely, in addition to the demonstration of significant in vivo
growth-inhibitory effect of rHuEPOα alone, this prospective
study also presents the novel observation that qRT-PCR
measurement of EPOR expression in bronchial brushes is a
useful tool to predict outcomes in patients with advanced stage
lung ADC. During the follow-up period, a significantly higher
incidence of death from lung ADC was found in patients with
low pretreatment EPOR levels as compared with those of high
EPOR levels. Although large-scale meta-analyses of clinical
trials on erythropoiesis-stimulating agents in various tumor
types [28], including NSCLC [29], suggest no effect of these
drugs on patients' prognosis, our results, therefore, support an
effect of rHuEPOα either directly or indirectly reducing
pulmonary ADC progression. The current preliminary study,
however, has to be confirmed in further studies in additional
cohorts of patients with lung ADC.
Materials and Methods
Cell lines
The H358, H1975 and H1650 ADC lines and the K562
erythroleukemia cells were obtained from the American Type
Culture Collection (Manassas, VA). All cell lines were cultured
in RPMI-1640 (Sigma Chemical Co., St. Louis, MO)
supplemented with 10% fetal bovine serum (Sigma) and 100
U/ml penicillin-100 Ag/ml streptomycin (Sigma). HUVECs were
isolated from fresh-term umbilical cords as described
previously [30], and were cultured in EBM-2 Basal Medium
(Lonza Cologne GmbH, Walkersville, MD) supplemented with
EC growth media (Lonza). All cell lines were maintained in at
37°C in a humidified incubator with 5% CO2.
Human samples and clinicopathological data
All patients gave their written informed consent and the
human sample collection was approved by the Scientific and
Research Ethics Committee of the Medical Research Council
of Hungary (153/PI/10; 2521-0/2010-1018EKU). A total of 43
patients with stage III-IV ADC treated in the National Koranyi
Institute of TB and Pulmonology, Hungary from January 2009
to December 2010 were included into the study.
For qRT-PCR analyses, bronchoscopy brushes of patients
with ADC were obtained and stored at -80°C until total RNA
isolation. In each patient two brushings were done, one from
normal endobronchial surface distant from the tumor site, and
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an other from the tumor tissue. Both samples underwent
examination by an expert cytologist as well.
There were 19 male and 24 female patients with a median
age of 61 (Table 1). The cases were staged according to
operative and pathologic findings based on The American Joint
Committee on Cancer/Union Internationale Contre le Cancer
TNM classification.
Measurement of EPOR expression on human samples
and tumor cell lines
The total mRNA of the samples and the cell lines were
extracted by TRI Reagent (Sigma). The extracted RNA was
purified with DNA-free DNase kit (Ambion, Austin, TX). 12,5 μl
of total RNA were reverse transcribed from each samples using
deoxy-NTPs, a mixture of random primer and oligodT, RNasin
ribonuclease inhibitor (20 U/reaction; Promega, Madison, WI),
reverse transcriptase buffer and M-MLV reverse transcriptase
(200 U/reaction, Sigma). They were incubated for 50 min at
37°C and then at 85°C for 10 min. The reverse transcription
and the lack of genomic DNA contamination was demonstrated
by primers specific for β-actin transcripts (sense: 5’-GTG GGG
CGC CCC AGG CAC CCA-3’ and antisense: 5’-CTC CTT AAT
GTC ACG CAC GAT TTC-3’). The real-time PCR reaction was
run on the Applied Biosystems 7500 PCR machine using
TaqMan Universal PCR Master mix and TaqMan premade
gene expression assays; EPOR: Hs000181092_m1; β-actin:
Hs03023880_g1; GAPDH: Hs02786624_g1 (Applied
Biosystems, Foster City, CA). The cycling parameters were as
follows: 2 minutes at 50°C, 40 cycles of 10 seconds at 95 °C, 1
minute at 60°C and 1 minute at 72°C. EPOR expression levels
of human samples were determined after normalization to β-
actin expression and to GAPDH in case of cell lines. The tumor
tissue EPOR expressions were normalized to the patient-
matched normal endobronchial EPOR expression levels (T/N).
In vitro cell proliferation assay
H358, H1975 and H1650 cells (5x103 per well) were plated
into 96-well tissue culture plate (6-6 parallel from each cell line/
treatment) in RPMI-1640 medium containing 10% fetal bovine
serum. After 24 hours, cell were treated for 48 hours in 150μl
Table 2. Multivariate analysis of various prognostic factors
in patients with advanced stage lung ADC.
Prognostic factor RR 95% CI P
Age 1.077 (1.017-1.142) 0.012
Gender (male vs. female) 0.364 (0.157-0.843) 0.018
Stage (III vs. IV) 0.615 (0.291-1.302) 0.204
Smoking (ever smokers vs never-smokers) 0.67 (0.258-1.741) 0.342
EPOR (low vs. high) 0.431 (0.201-0.926) 0.031
RR, relative risk; CI, confidence interval
doi: 10.1371/journal.pone.0077459.t002
Figure 4.  Low EPOR expression is associated with poor prognosis in advanced stage human pulmonary
adenocarcinoma.  (A) Kaplan-Meier curves for the overall survival of the entire patient population with stage III-IV ADC (n = 43),
according to high and low EPOR expression as determined by the ratio of tumor and normal bronchoscopy brush EPOR mRNA
expressions based on quantitative real-time PCR.
doi: 10.1371/journal.pone.0077459.g004
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medium containing 3% FBS. Treatments were as follows:
rHuEPOα (Jannsen-Cilag, Shaffhausen, Switzerland) at 1 and
3 IU/ml, gemcitabine (Gemzar, Lilly, France) at 1, 10 µg/ml and
the combination of rHuEPOα (1, 3 IU/ml) and gemcitabine (1,
10 µg/ml) simultaneously. After 48 hours, cell growth was
assessed by sulforhodamine B (SRB) colorimetric assay.
Briefly, the culture medium was aspirated prior to precipitation
of proteins with 10% trichloroacetic acid for 1 hour at 4°C. Then
cells were washed five times with deionized water and stained
for 15 minutes with 0.4% SRB dye in 1% acetic acid. To
remove unbound stain, plates were washed with 1% acetic acid
and left to dry at room temperature. Finally, the stained
proteins were solubilized in 10 mM Tris buffer. Absorbance was
measured at 570 nm by Varioskan microplate reader (Thermo
Fisher Scientific Inc., Waltham, MA, USA). The experiments
were repeated independently three times.
Xenograft tumors
The backs of female SCID (CB17/ICR-Prkdcscid) mice were
subcutaneously inoculated with 1,5x106 H1975 tumor cells. All
animal experiments were conducted following standards and
procedures approved by the Animal Care and Use Committee
of the National Institute of Oncology, Budapest
(22.1/1268/3/2010).
In vivo rHuEPOα and gemcitabine treatment
The first group of SCID mice was treated intraperitoneally
with rHuEPOα at human-equivalent dose (150 IU/kg in
physiological salt solution, final volume 0.1 ml) three times per
week from day 5 till day 33. The second group was treated
intraperitoneally four times with gemcitabine (100 mg/kg)
[31–33] on the day 20, 24, 27 and 31. The third group received
rHuEPOα intraperitoneally at human-equivalent dose thrice per
week from day 5 till day 33 and gemcitabine (100 mg/kg) on
day 20, 24, 27 and 31. Control animals were given
physiological salt solution only. Tumor volumes were measured
thrice per week from day 19 with a caliper and expressed in
cm3 by the formula for the volume of a prolate ellipsoid [length
× width2 × π/6].
Measurement of proliferation index
rHuEPOα-treated, tumor-bearing animals were injected
intraperitoneally with BrdU (200 mg/kg, Sigma). After 1 hour
incubation, tumors were removed and snap frozen. 5 μm frozen
sections were cut and immunostained, as described previously
[34]. BrdU-positive cells were detected by anti-BrdU
monoclonal antibody (Becton Dickinson, Bioscience, San Jose,
CA) and TRITC-conjugated anti-mouse IgG (1:100, Sigma).
Slides were then incubated with monoclonal rat anti-mouse
CD31 antibody (1:20, Becton Dickinson) followed by
biotinylated anti-rat IgG and streptavidin-FITC (Vector
Laboratories, Burlingame, CA) to discriminate ECs from tumor
cells. The nuclei were stained with TOTO-3 iodide (Invitrogen,
Carlsbad, CA, USA). The BrdU labeling index was determined
by counting non-labeled and labeled H1975 and mouse EC
nuclei in independent intratumoral areas. The labeling index
was calculated by dividing the number of labeled nuclei by the
total number of nuclei counted, as described previously
[22,34–37].
Statistical analysis
To determine statistical differences between two groups t-
test was used. ANOVA was used with the post hoc Scheffé- or
Bonferroni-tests for the comparison of more than two groups.
For the animal experiments we used the non-parametric Mann-
Whitney U-test. Categorical data were compared using Fishers’
exact probability and chi-square tests. Overall survival
analyses were done using the Kaplan-Meier method. Overall
survival intervals were determined as the time period from
initial diagnosis to the time of death. The comparison between
survival functions for different strata was assessed with the log-
rank statistics. Multivariate analysis of the clinical parameters
was performed using Cox’s regression model. Statistical
significance was determined when P values were <0.05.
Statistical analysis was performed using GraphPad Prism 5.0
software (GraphPad Inc., San Diego, CA, USA) for preclinical
data and Statistica 9.0 software for the clinical data (StatSoft,
Tulsa, OK, USA).
Supporting Information
Figure S1.  EPOR expression measured in tumoral (T) and
normal (N) pairs of tissue samples of pulmonary ADC
patients. For qRT-PCR measurement, RNA was isolated from
bronchoscopy brushes of ADC patients. Two samples were
taken in each patient, one from the tumor site (T), and an other
from the tumor-free endobronchial surface (N).
(TIF)
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